Shares of Luminex Corp. (NASDAQ:LMNX) have been assigned an average rating of “Hold” from the seven analysts that are covering the firm. Six analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $22.80.
A number of analysts have recently weighed in on the company. Avondale Partners assumed coverage on Luminex Corp. in a research report on Wednesday, October 12th. They set an “outperform” rating and a $27.00 price target on the stock. Jefferies Group increased their price target on Luminex Corp. from $21.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, July 28th. Zacks Investment Research raised Luminex Corp. from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a report on Tuesday, July 26th. Finally, JPMorgan Chase & Co. raised Luminex Corp. from an “underweight” rating to a “neutral” rating and increased their price objective for the stock from $18.00 to $22.00 in a report on Thursday, August 18th.
Luminex Corp. (NASDAQ:LMNX) opened at 22.09 on Friday. Luminex Corp. has a 12-month low of $17.29 and a 12-month high of $23.75. The firm has a market capitalization of $961.98 million, a PE ratio of 23.06 and a beta of 0.42. The stock has a 50 day moving average price of $22.11 and a 200-day moving average price of $21.05.
Luminex Corp. (NASDAQ:LMNX) last announced its quarterly earnings results on Thursday, July 28th. The company reported $0.33 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.18. The business had revenue of $64.20 million for the quarter, compared to analysts’ expectations of $61.20 million. Luminex Corp. had a return on equity of 13.65% and a net margin of 16.60%. The business’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.27 EPS. On average, equities research analysts forecast that Luminex Corp. will post $0.63 EPS for the current year.
A number of institutional investors have recently modified their holdings of LMNX. Teacher Retirement System of Texas raised its position in shares of Luminex Corp. by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 5,429 shares of the company’s stock worth $110,000 after buying an additional 659 shares during the last quarter. Mason Street Advisors LLC purchased a new position in shares of Luminex Corp. during the second quarter worth about $153,000. Creative Planning raised its position in shares of Luminex Corp. by 1.6% in the third quarter. Creative Planning now owns 8,923 shares of the company’s stock worth $203,000 after buying an additional 141 shares during the last quarter. Huntington Asset Advisors Inc. purchased a new position in shares of Luminex Corp. during the first quarter worth about $194,000. Finally, Legal & General Group Plc raised its position in shares of Luminex Corp. by 30.9% in the second quarter. Legal & General Group Plc now owns 10,357 shares of the company’s stock worth $207,000 after buying an additional 2,446 shares during the last quarter. 79.83% of the stock is owned by hedge funds and other institutional investors.
Luminex Corp. Company Profile
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry.
Receive News & Ratings for Luminex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corp. and related companies with MarketBeat.com's FREE daily email newsletter.